Skip to content

Effect analysis of the application of different doses of remimazolam besylate in painless gastroscopy

Effect analysis of the application of different doses of remimazolam besylate in painless gastroscopy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089070
Enrollment
Unknown
Registered
2024-09-01
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastrointestinal endoscopy

Interventions

Remazolam benzoate 0.20mg/kg group :Remazolam benzoate 0.20mg/kg
Remazolam benzoate 0.25mg/kg group :Remazolam benzoate 0.25mg/kg
Remazolam benzoate 0.30mg/kg group :Remazolam benzoate 0.30mg/kg

Sponsors

The First Affiliated Hospital of Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-65 years old, (2) Body mass index (BMI) < 28kg/?, (3) Acceptable for gastrointestinal endoscopy (4) United States Association of Anesthesiologists (ASA) classification I-III.

Exclusion criteria

Exclusion criteria: (1) Those who are allergic to benzodiazepines (2) Those who use analgesics and benzodiazepines for a long time (3) Those who have a history of major heart, lung, liver or kidney diseases and patients with myasthenia gravis (4) Those who have schizophrenia or severe depression (5) Those who have long-term alcohol or drug abuse (6) Those who have a history of difficult tracheal intubation (7) Pregnant women

Design outcomes

Primary

MeasureTime frame
Mean arterial pressure, MAP;Heart rate, HR;SpO2;

Countries

China

Contacts

Public ContactZhu Sujie

The First Affiliated Hospital of Xinjiang Medical University

1479572172@qq.com+86 132 0126 9939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026